Journals / Pamukkale Tıp Dergisi / 2023 / Cilt: 16 - Sayı: 1

Evaluation of the relationship between surfactant protein D levels and COVID-19 clinical severity: a case-control study

Sürfaktan protein D düzeyleri ile COVID-19 klinik şiddeti arasindaki ilişkinin değerlendirilmesi: bir vaka kontrol çalışması

Pages
137–147
Publication Date
2023-01-31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Furthermore, SP-D levels were 86% sensitive and 51.6% specific at 2.44 ng/mllevel (p=0.004) to detect severe/critical patients.Conclusion: SP-D levels is useful for COVID-19 patients in the prediction of clinical severity and prognosis.SP-D is a valuable biomarker for predicting the clinical severity and prognosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: Serum surfactant protein D (SP-D) plays roles in the body such as protection against viral infection,bacterial and fungal clearance, clearance of apoptotic cells and suppression of inflammation.
📊
Key Findings & Data:This study aims toexamine the relationship between SP-D level and coronavirus disease (COVID-19) severity.Methods: 80 patients (30 with mild disease and 50 with severe/critical COVID-19), and 50 healthy volunteerswere enrolled in the study.
💡
Conclusion & Impact:Furthermore, SP-D levels were 86% sensitive and 51.6% specific at 2.44 ng/mllevel (p=0.004) to detect severe/critical patients.Conclusion: SP-D levels is useful for COVID-19 patients in the prediction of clinical severity and prognosis.SP-D is a valuable biomarker for predicting the clinical severity and prognosis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Sürfaktan protein D · COVID-19 · pnömoni

Abstract

Purpose: Serum surfactant protein D (SP-D) plays roles in the body such as protection against viral infection,bacterial and fungal clearance, clearance of apoptotic cells and suppression of inflammation. This study aims toexamine the relationship between SP-D level and coronavirus disease (COVID-19) severity.Methods: 80 patients (30 with mild disease and 50 with severe/critical COVID-19), and 50 healthy volunteerswere enrolled in the study. SP-D levels were analyzed by ELISA in serum samples.Results: The median of SP-D was found to be 2.47 (1.67-7.79) ng/ml in mild disease and 5.65 (3.09-16.55) ng/ml in severe/critical disease groups, while 2.89 (10.8-6.24) ng/ml in the healthy controls. The differences in SP-Dlevels between the severe/critical disease group compared to both mild disease and control groups were foundstatistically significant (p=0.007 and 0.001, respectively). ROC analysis showed greater AUC for the serumSP-D levels of the severe/critical COVID-19 patients compared to mild COVID-19 disease patients (AUC=0,691,95% CI=0.56-0,822; p=0.004). Furthermore, SP-D levels were 86% sensitive and 51.6% specific at 2.44 ng/mllevel (p=0.004) to detect severe/critical patients.Conclusion: SP-D levels is useful for COVID-19 patients in the prediction of clinical severity and prognosis.SP-D is a valuable biomarker for predicting the clinical severity and prognosis.

Özet

Amaç: Serum surfaktan protein D (SP-D) vücutta viral enfeksiyona karşı koruma, bakteriyel ve fungal klirens,apoptotik hücrelerin temizlenmesi ve inflamasyonun baskılanması gibi roller oynar. Bu çalışma, SP-D düzeyi ilekoronavirüs hastalığı (COVID-19) şiddeti arasındaki ilişkiyi incelemeyi amaçlamaktadır.Gereç ve yöntem: Çalışmaya 80 hasta (30 hafif hastalığı ve 50 ağır/kritik COVID-19) ve 50 sağlıklı gönüllü dahiledildi. Serum örneklerinde SP-D seviyeleri ELISA ile analiz edildi.Bulgular: SP-D düzeyi ortanca değeri hafif hastalıkta 2,47 (1,67-7,79) ng/ml, ağır/kritik hastalık gruplarında5,65 (3,09-16,55) ng/ml iken, sağlıklı control grubunda 2,89 (10,8-6,24) ng/ml olarak bulundu. Ağır/kritik hastalıkgrubu hem hafif hastalık hem de kontrol grubu ile karşılaştırıldığında SP-D düzeylerindeki farklılıklar istatistikselolarak anlamlı bulundu (sırasıyla p=0,007 ve 0,001). ROC analizi, hafif COVID-19 hastalığı hastalarına kıyaslaşiddetli/kritik COVID-19 hastalarında serum SP-D seviyeleri için eğri altında kalan alan daha yüksek saptandı(AUC=0.691, %95 CI=0,56-0.822; p=0,004). Ayrıca, ağır/kritik hastaları saptamak için SP-D düzeyleri 2,44 ng/ml düzeyinde (p=0,004) %86 duyarlı ve %51,6 özgül saptandı.Sonuç: SP-D seviyeleri, COVID-19 hastaları için klinik şiddeti ve prognozu tahmin etmede faydalıdır. SP-D,klinik şiddeti ve prognozu tahmin etmek için değerli bir biyobelirteçtir.

🔖

Cite This Article

KARSLI, E., SABIRLI, R., GÖREN, T., KEMANCI, A., KARIŞ, D., TÜRKÇÜER, İ., KURT, Ö., BERTRAND, P., KOSELER, A. (2023). Evaluation of the relationship between surfactant protein D levels and COVID-19 clinical severity: a case-control study. Pamukkale Tıp Dergisi, Cilt: 16 - Sayı: 1, 137–147. https://ajindex.com/articles/876224

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. CDC. 2019 Novel Coronavirus, Wuhan, China. CDC. Available at https://www.cdc.gov/coronavirus/2019-ncov/about/index.html. January 26, 2020; Accessed: January 27, 2020
  2. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-.19) (Updated 2020 Aug 10). In: StatPearls (Internet). Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from:
  3. Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 2020;55:102763. doi: 10.1016/j.ebiom.2020.102763
  4. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020;109:102433. doi: 10.1016/j.jaut.2020.102433
  5. Mason RJ. Biology of alveolar type II cells. Respirology 2006;11 Suppl:S12-15. doi: 10.1111/j.1440-1843.2006.00800.x
  6. Bernhard W. Lung surfactant: Function and composition in the context of development and respiratory physiology. Ann Anat 2016;208:146-150. doi: 10.1016/j.aanat.2016.08.003
  7. Kishore U, Greenhough TJ, Waters P, et al. Surfactant proteins SP-A and SP-D: structure, function and receptors. Mol Immunol 2006;43:1293-315. doi: 10.1016/j.molimm.2005.08.004
  8. Mori K, Kurihara N, Hayashida S, Tanaka M, Ikeda K. The intrauterine expression of surfactant protein D in the terminal airways of human fetuses compared with surfactant protein Eur J Pediatr 2002;161:431-4. doi: 10.1007/s00431-002-0917-9
  9. Knudsen L, Ochs M, Mackay R, et al. Truncated recombinant human SP-D attenuates emphysema and type II cell changes in SP-D deficient mice. Respir Res 2007;8:70. doi: 10.1186/1465-9921-8-70
  10. Ohnishi H, Yokoyama A, Kondo K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 2002;165:378-81. doi: 10.1164/ajrccm.165.3.2107134
  11. Sims MW, Tal-Singer RM, Kierstein S, Musani AI, Beers MF, Panettieri RA, Haczku A. Chronic obstructive pulmonary disease and inhaled steroids alter surfactant protein D (SP-D) levels: a cross-sectional study. Respir Res 2008 Jan 28;9:13. doi: 10.1186/1465-9921-9-13
  12. Nakamura K, Kato M, Shukuya T, et al. Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case contro